Literature DB >> 33323405

Unbiased Detection of Driver Mutations in Extramammary Paget Disease.

Yoshihiro Ishida1, Nobuyuki Kakiuchi2, Kenji Kabashima1, Seishi Ogawa3, Kenichi Yoshida2, Yoshikage Inoue2, Hiroyuki Irie1, Tatsuki R Kataoka4, Masahiro Hirata4, Takeru Funakoshi5, Shigeto Matsushita6, Hiroo Hata7, Hiroshi Uchi8, Yuki Yamamoto9, Yasuhiro Fujisawa10, Taku Fujimura11, Ryunosuke Saiki2, Kengo Takeuchi12,13,14, Yuichi Shiraishi15, Kenichi Chiba15, Hiroko Tanaka16, Atsushi Otsuka1, Satoru Miyano16.   

Abstract

PURPOSE: Extramammary Paget disease (EMPD) is an uncommon skin malignancy whose genetic alterations are poorly characterized. Previous reports identified mutations in chromatin remodeling genes and PIK3CA. In order to unambiguously determine driver mutations in EMPD, we analyzed 87 EMPD samples using exome sequencing in combination with targeted sequencing. EXPERIMENTAL
DESIGN: First, we analyzed 37 EMPD samples that were surgically resected using whole-exome sequencing. Based on several in silico analysis, we built a custom capture panel of putative driver genes and analyzed 50 additional formalin-fixed, paraffin-embedded samples using target sequencing. ERBB2 expression was evaluated by HER2 immunohisotochemistry. Select samples were further analyzed by fluorescence in situ hybridization.
RESULTS: A median of 92 mutations/sample was identified in exome analysis. A union of driver detection algorithms identified ERBB2, ERBB3, KMT2C, TP53, PIK3CA, NUP93, AFDN, and CUX1 as likely driver mutations. Copy-number alteration analysis showed regions spanning CDKN2A as recurrently deleted, and ERBB2 as recurrently amplified. ERBB2, ERBB3, and FGFR1 amplification/mutation showed tendency toward mutual exclusivity. Copy-number alteration load was associated with likelihood to recur. Mutational signatures were dominated by aging and APOBEC activation and lacked evidence of ultraviolet radiation. HER2 IHC/fluorescence in situ analysis validated ERBB2 amplification but was underpowered to detect mutations. Tumor heterogeneity in terms of ERBB2 amplification status was observed in some cases.
CONCLUSIONS: Our comprehensive, unbiased analysis shows EMPD is characterized by alterations involving the PI3K-AKT pathway. EMPD is distinct from other skin cancers in both molecular pathways altered and etiology behind mutagenesis. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33323405     DOI: 10.1158/1078-0432.CCR-20-3205

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  7 in total

1.  Treatment of Metastatic Primary Extramammary Paget Disease With Combination Anlotinib and Tislelizumab: A Case Report and Review of the Literature.

Authors:  Xin Yin; Xiaoqing Li; Muli Li; Qing She; Yan Liu; Xiaodan Chen; Suhua Ma; Qian Ma; Zhangkan Huang; Lin Xu; Xiaozhun Huang; Zhengyin Zhan; Xu Che
Journal:  Front Med (Lausanne)       Date:  2022-05-24

Review 2.  Current Management and Treatment of Extramammary Paget's Disease.

Authors:  Hiroki Hashimoto; Takamichi Ito
Journal:  Curr Treat Options Oncol       Date:  2022-04-04

3.  Absence of microsatellite instability in extramammary Paget's disease.

Authors:  K Kashiwada-Nakamura; T M Myangat; I Kajihara; Y Kusaba; K Tanaka; R Sakamoto; S Maeda-Otsuka; S Yamada-Kanazawa; S Sawamura; H Kanemaru; Y Nishimura; N Honda; K Makino; A Miyashita; J Aoi; T Igata; T Makino; S Masuguchi; S Fukushima; H Ihn
Journal:  Skin Health Dis       Date:  2021-05-05

4.  CDK4: A Novel Therapeutic Target for Extramammary Paget's Disease.

Authors:  Hiroki Hashimoto; Yumiko Kaku-Ito; Yoshinao Oda; Takamichi Ito
Journal:  Front Oncol       Date:  2021-07-29       Impact factor: 6.244

5.  Cyclin-dependent kinase 4/6 inhibitors suppress tumor growth in extramammary Paget's disease.

Authors:  Shinya Kitamura; Teruki Yanagi; Takuya Maeda; Hideyuki Ujiie
Journal:  Cancer Sci       Date:  2021-12-13       Impact factor: 6.716

6.  HER2-Targeted Antibody-Drug Conjugates Display Potent Antitumor Activities in Preclinical Extramammary Paget's Disease Models: In Vivo and Immunohistochemical Analyses.

Authors:  Keiko Tokuchi; Takuya Maeda; Shinya Kitamura; Teruki Yanagi; Hideyuki Ujiie
Journal:  Cancers (Basel)       Date:  2022-07-20       Impact factor: 6.575

7.  Cell origin and genome profile difference of penoscrotum invasive extramammary Paget disease compared with its in situ counterpart.

Authors:  Yamin Rao; Jinchao Zhu; Haiyan Zheng; Yong Ren; Tianhai Ji
Journal:  Front Oncol       Date:  2022-08-24       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.